Rodman & Renshaw Starts Rigel Pharma (RIGL) at Market Outperform, Multi-Billion Drug Potential
More News related to RIGL
- Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting
- Morning Movers 11/23: ABIO, SEED, FIF, FNET, DDRX, JOBS Higher; BBI, CGA, BOFL, CEPH Lower
- RBC Upgrades Rigel Pharmaceuticals (RIGL) to Outperform
- Rigel Announces Third Quarter 2009 Financial Results
- Rigel Announces Presentations at Two Investor Conferences
More News related to New Coverage
- C. K. Cooper & Company Initiates Coverage of UNIT Corporation (UNT)
- Morgan Stanley Initiates Coverage on ConAgra Foods (CAG) with a Equalweight
- Stifel Nicolaus Initiates Coverage on Simmons First National (SFNC) with a Hold
- Cowen & Co Initiates Coverage on Roche (RHHBY) with an Outperform
- BB&T Capital Initiates Coverage on MYR Group (MYRG) with a Hold
Rodman & Renshaw initiated coverage on Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) with a Market Outperform rating and $33 price target.
The firm said Rigel's R788 in an oral DMARD with multi-billion dollar potentail in rheumatoid arthritis (RA).
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.
Related Categories
New CoverageStocks Mentioned
+0.36Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
